De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.
Sieja
Kevin S
KS
Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80220, USA. Kevin.Sieja@uchsc.edu
Everson
Gregory T
GT
D000998:Antiviral Agents / Q000627:therapeutic use*; D001707:Biopsy, Needle; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000601:surgery; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007372:Interferons / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery; D016031:Liver Transplantation / Q000379:methods; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons